Galapagos is a fully integrated biotechnology company united around a single purpose: to transform patient outcomes through life-changing science and innovation for more years of life and quality of life. We focus on the key therapeutic areas of immunology and oncology, where we have developed deep scientific expertise in multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to commercialized programs and our first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.
Galapagos has more than 1,200 employees worldwide, with sites in Belgium (international headquarters), the Netherlands, France, Germany, Italy, Spain, Switzerland, the UK and the US.
For additional information, please visit www.glpg.com or follow us on LinkedIn or Twitter.
We aim to discover and develop medicines to contribute to the quality of life of patients around the world. These patients and their physicians place their trust in us and our medicines. Trust comes with responsibility. Therefore, we apply high ethical standards in all of our business areas. Everyone working for and with Galapagos is expected to adhere to these standards.
The Baloise Park
Galapagos was founded in 1999 as a joint venture between Crucell and Tibotec.
In 2005, the Company listed on Euronext Brussels and Amsterdam (ticker symbol: GLPG).
In 2006, Galapagos acquired ProSkelia in Romainville, France, obtaining R&D operations there.
In 2010, Galapagos acquired the Zagreb research operations from GSK; this site became Fidelta, a drug discovery fee-for-service business within the Galapagos group. Fidelta was subsequently acquired by Selvita in 2020.
In 2015, Galapagos listed on the US NASDAQ (ticker symbol: GLPG).
In 2015, Galapagos signed a collaboration agreement with Gilead for the development and commercialization of filgotinib.
In 2019, Galapagos entered into a transformative 10-year global research and development collaboration with Gilead.
In 2020, our first medicine Jyseleca® (filgotinib) was granted marketing authorization for the treatment of rheumatoid arthritis in the EU and Japan, marking Galapagos’ transition to commercial-stage biotech.
In 2021, our first medicine Jyseleca® (filgotinib) was approved in Europe for the treatment of ulcerative colitis.
In 2022, Galapagos acquired CellPoint and AboundBio, propelling the company into oncology, CAR-T and biologicals.
In addition, our first medicine Jyseleca® (filgotinib) was approved in Great Britain and Japan for ulcerative colitis.
Galapagos GmbH
Baloise Park West
22. und 23. OG
Aeschengraben 27
4051 Basel
Switzerland
Email: Reception_Bas [at] glpg.com